Boulder iQ Showcases Comprehensive Support at 2025 RESI Conference
Boulder iQ, a leader in the realm of life science consulting, is set to make a notable presence at the upcoming Redefining Every Stage of Investment (RESI) conference scheduled for June 16, 2025, in Boston. This event is increasingly significant as it connects burgeoning life science enterprises with crucial investors and strategic partners, paving the path for funding and development opportunities.
As a seasoned contract consulting firm, Boulder iQ specializes in delivering an all-encompassing suite of services that life science developers require to successfully launch their products in the market. These services include product design and development, regulatory compliance, manufacturing and assembly, sterilization processes, as well as packaging and labeling. Jim Kasic, the president and CEO of Boulder iQ, articulates the company's role, stating, "We're a strategic partner in the business of helping early-stage companies speed their products to market. When companies receive the necessary funding to proceed, we guide them through the intricate development processes efficiently and affordably."
The RESI conference will draw several hundred investors along with strategic partners, offering a dynamic platform for early-stage life science companies to seek funding and cultivate relationships. This collaboration is vital for startups, as they not only seek financial backing but also support for their preliminary projects which are essential for their commercial success.
Kasic further emphasizes the unique landscape in which these startups operate, noting, "The industry presents limited opportunities for early-stage companies to secure full support from concept through to manufacturing with experienced professionals. RESI provides a dedicated venue for us to pinpoint companies that are eager to transition their primary technologies toward commercialization while requiring responsive product development support."
Boulder iQ, based in Boulder, Colorado, is fortified by its ISO 13485:2016 certification through Boulder BioMed, ensuring it adheres to stringent quality management systems that enhance the reliability of the services provided. The company's efforts are further bolstered by its sister firms: Boulder Sterilization and Boulder Regulatory Affairs and Quality Assurance. These specialized entities work collaboratively to expedite the market readiness of products. Boulder Sterilization is particularly noteworthy for its prompt ethylene oxide (EO) and chlorine dioxide (CD) sterilization services tailored for medical devices and in-vitro diagnostic products. Boulder Regulatory Affairs assists with comprehensive regulatory frameworks and quality assurance, serving as a critical component in the journey of life science enterprises.
As the RESI conference approaches, Boulder iQ stands ready to exemplify how strategic partnerships and expert support can empower life science innovators to navigate challenges effectively and succeed in delivering life-saving products to the market. The firm’s commitment to quality and efficiency positions it as a vital ally for any startup navigating the complexities of product development in the life science sector.